Doctors in Noida have reported a major advance in psoriasis treatment after a young patient saw near-complete clearance of ...

Novartis’ ITVISMA, approved a month ago by the US FDA, used at Sheikh Khalifa Medical City under the supervision of the ...

Under the supervision of the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...

Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

The extreme weight loss seen in many late-stage cancer patients, known as cachexia, is far more than a cosmetic side effect.

Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of all disease-related ...

Praxis said it is on track for filing for FDA approval of ulixacaltamide in early 2026. Praxis shares were recently changing hands at $300.74, up nearly 13%. Write to Colin Kellaher at ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...